Aberdeen Wealth Management LLC Sells 482 Shares of Bristol-Myers Squibb (NYSE:BMY)

Aberdeen Wealth Management LLC cut its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 7.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,437 shares of the biopharmaceutical company’s stock after selling 482 shares during the quarter. Aberdeen Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $333,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in BMY. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth approximately $4,010,000. First City Capital Management Inc. raised its holdings in shares of Bristol-Myers Squibb by 11.3% in the 3rd quarter. First City Capital Management Inc. now owns 20,945 shares of the biopharmaceutical company’s stock worth $1,084,000 after acquiring an additional 2,120 shares during the last quarter. Prospera Financial Services Inc raised its stake in shares of Bristol-Myers Squibb by 40.0% in the third quarter. Prospera Financial Services Inc now owns 73,255 shares of the biopharmaceutical company’s stock worth $3,791,000 after purchasing an additional 20,916 shares during the last quarter. Verity & Verity LLC bought a new position in Bristol-Myers Squibb during the 3rd quarter valued at $226,000. Finally, Meeder Asset Management Inc. lifted its position in shares of Bristol-Myers Squibb by 93.8% during the third quarter. Meeder Asset Management Inc. now owns 31,672 shares of the biopharmaceutical company’s stock valued at $1,639,000 after purchasing an additional 15,329 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Analysts Set New Price Targets

BMY has been the subject of several recent analyst reports. Morgan Stanley upped their target price on Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Sanford C. Bernstein started coverage on Bristol-Myers Squibb in a research note on Thursday, October 17th. They set a “market perform” rating and a $56.00 price target for the company. Jefferies Financial Group lifted their price objective on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research note on Wednesday, August 28th. Finally, Daiwa America raised shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 13th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, two have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $54.07.

Bristol-Myers Squibb Price Performance

Shares of NYSE BMY opened at $56.81 on Tuesday. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The firm’s fifty day moving average is $52.90 and its 200 day moving average is $47.37. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.08.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. During the same quarter last year, the firm posted $2.00 earnings per share. The firm’s revenue was up 8.4% compared to the same quarter last year. As a group, analysts predict that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were given a dividend of $0.60 per share. The ex-dividend date was Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.22%. Bristol-Myers Squibb’s payout ratio is currently -66.85%.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,830 shares of Bristol-Myers Squibb stock in a transaction dated Friday, November 1st. The shares were purchased at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the acquisition, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. This represents a 3.04 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.